25-Feb-2026 3:05 PM CST - Business Wire Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December 31, 2025. We delivered an exceptional finish to 2025, with strong double-digit growth across both Decipher and Afirma and more than 45,000 patients served with our core testing business in the quarter, said Marc Stapley, Veracytes chief executive officer. We are achieving this growth while mai
19-Feb-2026 4:00 PM CST - Business Wire Veracyte to Participate in Upcoming Investor Conferences Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 47th Annual Institutional Investors Conference Orlando, FL Presentation on March 3rd at 8:05 a.m. Eastern Time Leerink Partners Global Health Conference Miami, FL Fireside chat on March 9th at 10:40 a.m. Eastern Time Live audio webcasts of the companys presentations will be available by vi
4-Feb-2026 4:15 PM CST - Business Wire Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the companys
11-Jan-2026 3:30 PM CST - Business Wire Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. Preliminary Unaudited Financial Results For the fourth quarter ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report: Total revenue of between $138 million and $140 million, an increase of between 16% and 18% Testing revenue of
29-Dec-2025 3:30 PM CST - Business Wire Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 9:45 a.m. Pacific Time. Live audio webcasts of the companys presentations will be available by visiting Veracytes website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 30 days following the conclu
6-Nov-2025 7:30 AM CST - Business Wire Veracyte to Participate in Upcoming Investor Conferences Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Wolfe Research Healthcare Conference New York, NY Fireside Chat on November 17th at 10:00 a.m. Eastern Time Jefferies Global Healthcare Conference London, UK Fireside Chat on November 20th at 11:30 a.m. Greenwich Mean Time Stephens Annual Investment Conference Nashville, TN Fireside Chat on November 20t
4-Nov-2025 3:05 PM CST - Business Wire Veracyte Announces Third Quarter 2025 Financial Results Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. We delivered another outstanding quarter of testing revenue growth and adjusted EBITDA margin expansion, enabling us to raise both our revenue and profitability guidance, said Marc Stapley, Veracytes chief executive officer. We continue to advance our mission of transforming cancer care by generat
15-Oct-2025 4:31 PM CST - Business Wire Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025 after the close of market on Tuesday, November 4, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the companys website and wi
29-Aug-2025 7:30 AM CST - Business Wire Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference Veracyte, Inc. (Nasdaq: VCYT) announced today that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 p.m. Eastern Time. A live audio webcast of the companys presentation will be available by visiting Veracytes website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 90 days after the live presentatio
Latest VCYT Trades by Congress Members
18-FEB-2026 - Gilbert Cisneros, CA (District 31) purchased between $1,001 and $15,000.
25-Feb-2026 3:05 PM CST - Business Wire Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the fourth quarter and full year ended December 31, 2025. We delivered an exceptional finish to 2025, with strong double-digit growth across both Decipher and Afirma and more than 45,000 patients served with our core testing business in the quarter, said Marc Stapley, Veracytes chief executive officer. We are achieving this growth while mai
19-Feb-2026 4:00 PM CST - Business Wire Veracyte to Participate in Upcoming Investor Conferences Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Raymond James 47th Annual Institutional Investors Conference Orlando, FL Presentation on March 3rd at 8:05 a.m. Eastern Time Leerink Partners Global Health Conference Miami, FL Fireside chat on March 9th at 10:40 a.m. Eastern Time Live audio webcasts of the companys presentations will be available by vi
4-Feb-2026 4:15 PM CST - Business Wire Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026 Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the companys
11-Jan-2026 3:30 PM CST - Business Wire Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. Preliminary Unaudited Financial Results For the fourth quarter ended December 31, 2025, as compared to the same period of 2024, Veracyte expects to report: Total revenue of between $138 million and $140 million, an increase of between 16% and 18% Testing revenue of
29-Dec-2025 3:30 PM CST - Business Wire Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, at 9:45 a.m. Pacific Time. Live audio webcasts of the companys presentations will be available by visiting Veracytes website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 30 days following the conclu
6-Nov-2025 7:30 AM CST - Business Wire Veracyte to Participate in Upcoming Investor Conferences Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. Wolfe Research Healthcare Conference New York, NY Fireside Chat on November 17th at 10:00 a.m. Eastern Time Jefferies Global Healthcare Conference London, UK Fireside Chat on November 20th at 11:30 a.m. Greenwich Mean Time Stephens Annual Investment Conference Nashville, TN Fireside Chat on November 20t
4-Nov-2025 3:05 PM CST - Business Wire Veracyte Announces Third Quarter 2025 Financial Results Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025. We delivered another outstanding quarter of testing revenue growth and adjusted EBITDA margin expansion, enabling us to raise both our revenue and profitability guidance, said Marc Stapley, Veracytes chief executive officer. We continue to advance our mission of transforming cancer care by generat
15-Oct-2025 4:31 PM CST - Business Wire Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025 Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025 after the close of market on Tuesday, November 4, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the companys website and wi
29-Aug-2025 7:30 AM CST - Business Wire Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference Veracyte, Inc. (Nasdaq: VCYT) announced today that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 p.m. Eastern Time. A live audio webcast of the companys presentation will be available by visiting Veracytes website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 90 days after the live presentatio
